First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. :

--- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19.

If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide."

The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. : --- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide." The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
WWW.NEWSWEEK.COM
What is Molnupiravir? First oral COVID treatment could be issued by year's end
The companies said that an interim analysis found molnupiravir reduced the risk of hospitalization or death by approximately 50 percent..
0 Comentários 2 Compartilhamentos 838 Visualizações
Patrocinado

We are 100% funded for October.

Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Xephula Funding Meter

Please Donate Here